| Autor: |
Egaña L; Donostia University Hospital, Paseo Dr. Beguiristain, 20014, San Sebastian, Spain. larraitz.eganaotano@osakidetza.eus.; Biodonostia Health Research Institute, San Sebastian, Spain. larraitz.eganaotano@osakidetza.eus., Auzmendi-Iriarte J; Biodonostia Health Research Institute, San Sebastian, Spain., Andermatten J; Donostia University Hospital, Paseo Dr. Beguiristain, 20014, San Sebastian, Spain., Villanua J; Biodonostia Health Research Institute, San Sebastian, Spain.; Osatek Institute of Radiology, San Sebastian, Spain., Ruiz I; Donostia University Hospital, Paseo Dr. Beguiristain, 20014, San Sebastian, Spain.; Biodonostia Health Research Institute, San Sebastian, Spain., Elua-Pinin A; Donostia University Hospital, Paseo Dr. Beguiristain, 20014, San Sebastian, Spain., Aldaz P; Biodonostia Health Research Institute, San Sebastian, Spain., Querejeta A; Donostia University Hospital, Paseo Dr. Beguiristain, 20014, San Sebastian, Spain., Sarasqueta C; Biodonostia Health Research Institute, San Sebastian, Spain., Zubia F; Donostia University Hospital, Paseo Dr. Beguiristain, 20014, San Sebastian, Spain.; University of the Basque Country, Bilbao, Spain., Matheu A; Biodonostia Health Research Institute, San Sebastian, Spain.; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.; CIBERfes, Madrid, Spain., Samprón N; Donostia University Hospital, Paseo Dr. Beguiristain, 20014, San Sebastian, Spain.; Biodonostia Health Research Institute, San Sebastian, Spain. |
| Abstrakt: |
O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital. Surprisingly, methylation of MGMT promoter did not predict response to temozolomide in patients with glioblastoma in Donostia Hospital. Specifically, overall survival (OS) and progression-free survival (PFS) did not differ significantly by MGMT methylation status in our cohort. In contrast, both were longer in patients who received treatment, received more TMZ cycles, had a better general status and perform at least a partial resection. No association was detected between methylation of MGMT promoter and molecular markers such as ATRX, IDH, p53 and Ki67. These results indicate that MGMT methylation did not influence in patient survival in our cohort. |
